of CENP-E stepping on the resisting force was similar on these two lattices. The average dwell time between the steps for the entire force range was also similar on T-and D-MTs ( fig. S9G ). We further observed a slightly shorter dwell time at low force on D-MTs, which is consistent with the faster velocity of CENP-E walking on this type of microtubules (Fig. 2G) . CENP-E responded to larger loads by lengthening its dwells on D-MTs, but not on T-MTs. Under the load, CENP-E also detached less frequently from D-MTs (Fig. 2H) . As a result, the peak force for CENP-E detachment was shifted to significantly higher values on D-MTs (Fig. 2I) , indicating that the effect of tubulin detyrosination is exerted mostly on CENP-E detachment, rather than stepping. Thus, CENP-E can carry a significantly larger load on D-MTs in vitro.
Our data support a model in which CENP-E-dependent transport of pole-proximal chromosomes toward the spindle equator requires microtubule tracks that are detyrosinated. Therefore, increasing tubulin detyrosination should disrupt the biased motion of pole-proximal chromosomes toward the equator and cause their delivery to inappropriate cellular locations. To test this, we increased tubulin detyrosination by depleting TTL by means of RNA interference (RNAi) in U2OS cells ( fig. S10A ). TTL depletion caused ubiquitous detyrosination of spindle microtubules (including astral microtubules) during early mitosis (fig. S10B) (27) . Of TTL-depleted cells, 65% delayed mitotic progression and failed to congress all the chromosomes ( Fig. 3A and movie S5). In these cells, the pole-proximal chromosomes did not remain stuck at the spindle poles, as observed after CENP-E inhibition or after blocking tubulin detyrosination, but were transported in various directions, including toward the cell cortex (Fig. 3, A and B ). This suggests that the spatial cues that normally guide CENP-E toward the equator were disrupted. CENP-E inhibition in live TTL-depleted cells significantly decreased the transport of chromosomes away from spindle poles (Fig. 3, A and B) . This was confirmed in a large population of fixed cells by use of a quantitative monopolar spindle configuration assay (Fig. 4 , A to C) (1), indicating that the random transport of chromosomes along ubiquitously detyrosinated spindle microtubules after TTL RNAi is mediated by CENP-E.
Taken together, our work establishes the specific molecular mechanism that guides CENP-Edependent chromosome motion toward the cell equator. This mechanism is based on the ability of CENP-E to transport pole-proximal chromosomes preferentially on detyrosinated microtubule tracks, which are normally oriented toward the spindle equator ( fig. S11 ). We propose that microtubule detyrosination works as a navigation system that guides kinetochore motors during cell division, ultimately contributing to faithful chromosome segregation.
our laboratories for stimulating discussions. This work was supported by National Institutes of Health grant R01-GM098389 and RSG-14-018-01-CCG from the American Cancer Society to E.L.G.; by the Institut Curie, the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, the L'Agence Nationale de la Recherche (ANR) award  ANR-12-BSV2-0007, INCA_6517, ANR-10-LBX-0038, part of the  IDEX Idex PSL, ANR-10-IDEX- S1 ) (7) . All three patients had received prior treatment with ipilimumab (see supplementary materials). Exome sequencing was performed to identify somatic mutations in tumor samples (Fig. 1A) . Multiple metachronous tumors were analyzed from patients MEL21 and MEL38 (tables S1 and S2). Tumor missense mutations, translated as AAS-encoding nonamer peptides, were filtered through in silico analysis to assess HLA-A*02:01 peptide-binding affinity (8) , and expression of genes encoding predicted HLA-A*02:01 peptide candidates was determined by analysis of cDNA capture data ( Fig. 1A ) (9) . Peptide candidates for experimental validation were selected according to the strategy described in fig. S2 ; HLA-A*02:01 binding was evaluated using the T2 assay ( fig. S3 ) (10) and confirmed with the fluorescence polarizationbased competitive peptide-binding assay of Buchli et al. (11) . Seven AAS peptide candidates per patient were selected from validated HLA-A*02:01 binders ( fig. S2 and table S4) for incorporation into a personalized vaccine formulation, along with the melanoma gp100-derived peptides G209-2M and G280-9V as positive controls for vaccination (7) . The expression pattern of mutated genes encoding vaccine candidates is shown in Venn diagrams in Fig. 1A .
To examine the kinetics and magnitude of T cell immunity to AAS peptides upon vaccination, we collected peripheral blood mononuclear cells (PBMCs) prior to vaccination and weekly thereafter. The CD8 + T cell response to each peptide was analyzed using a HLA-A*02:01/AAS-peptide dextramer assay after a single round of in vitro stimulation ( fig. S4A) (7) . Immune monitoring demonstrated that in each patient, T cell immunity to one AAS peptide could be detected in prevaccine PBMC samples after in vitro stimulation (MEL21, TMEM48 F169L; MEL38, SEC24A P469L; MEL218, EXOC8 Q656P) (Fig. 1B) , although not directly from the blood ( fig. S4B ). Preexisting immunity to these three neoantigens was confirmed in ex vivo expanded, prevaccine-purified CD8 + T cells by means of dextramer assay ( fig. S4B ) and interferon (IFN)-g production (12) ( fig. S4C ).
Vaccination augmented the T cell response to these neoantigens, with observed frequencies of 23% TMEM48 F169L + CD8 + T cells, 64% SEC24A P469L + CD8 + T cells, and 89% EXOC8 Q656P + CD8 + T cells detected upon culture at the peak of response (Fig. 1B) . Immune monitoring also revealed vaccine-induced T cell immunity to two additional neoantigens per patient: TKT R438W and CDKN2A E153K (55% and 12%, respectively) in patient MEL21; AKAP13 Q285K and OR8B3 T190I (47% and 42%, respectively) in patient MEL38, and MRPS5 P59L and PABPC1 R520Q (58% and 84%, respectively) in patient MEL218 (Fig. 1B) . Two of the three patients, MEL21 and MEL218, had preexisting immunity to G209-2M and G280-9V peptides, as determined by the presence of gp100-specific T cells in prevaccine PBMC samples and their ex vivo expansion upon antigen stimulation ( fig. S5B ). Upon vaccination, these T cell responses were enhanced in patients MEL21 and MEL218 and revealed in patient MEL38 ( fig.  S5 ). No T cell immunity to the remaining 12 AAS peptides was detected. Overall, robust neoantigen T cell immunity was detectable as early as week 2 and peaked at week 8 to 9 after the initial vaccine dose ( fig. S4A ). Neoantigen-specific CD8 + T cells were readily identified by dextramer assay directly in postvaccine PBMC samples ( fig. S4B ) and memory T cells were detected up to 4 months after the final vaccine dose. Analysis of T cell reactivity among the three patients indicated no preferential skewing toward AAS at specific positions in the peptide sequencethat is, toward TCR contact residues or primary anchor residues (13) . Rather, in each patient, T cell immunity appeared to focus on the three AAS candidates exhibiting the highest HLA-A*02:01 binding affinity, whereas the remaining mediumto high-affinity peptides were nonimmunogenic (table S4) (8, 11) . Immunogenic AAS peptides (Fig. 1A) were not preferentially derived from genes with high allelic frequency or expression levels (tables S1 to S3).
To characterize the function of vaccine-induced neoantigen-specific T cells, we established shortterm expanded CD8 + T cell lines and confirmed their antigen specificity by dextramer assay ( fig.  S4B) (7, 12) . Neoantigen-specific T cells displayed significant levels of cytotoxic activity at AAS peptide concentrations of 1 to 10 nM, a finding that is consistent with high-avidity T cell recognition of antigen (Fig. 2A) . OR8B3 T190I-specific T cells could not discriminate between AAS and wildtype peptide when presented on T2 cells, whereas all of the remaining T cell lines showed clear specificity for AAS peptide sequences (Fig. 2A) . Next, we sought to characterize the cytokine production profile of these T cells, as a previous report suggests that IL-12p70-producing dendritic cells promote type 1 CD8 + T immunity, which in turn correlates with increased clinical benefit (7, 14) . Upon antigen stimulation, most vaccine-induced neoantigen-specific T cells produced high amounts of IFN-g relative to IL-4, IL-5, and IL-13-a pattern that is indicative of a type 1 phenotype ( fig. S6 ). However, SEC24A P469L-specific T cells exhibited a type 2-skewed phenotype (high IL-4, IL-5, and IL-13 levels relative to IFN-g), and TMEM48 F169L-specific T cells showed a mixed phenotype (high IL-13 levels, but not higher IL-4 or IL-5 levels, relative to IFN-g) ( fig. S6) TMEM48 F169L, TKT R438W, CDKN2A E153K,  SEC24A P469L, AKAP13 Q285K, EXOC8 Q656P , and PABPC1 R520Q-were processed and presented, as evidenced by cytotoxic activity (Fig. 2B ) and IFN-g production ( fig. S7C ) by corresponding neoantigen-specific T cells upon coculture with DM6 cells expressing AAS-encoding TMCs (AASTMCs). In contrast, neither cytotoxic activity (Fig. 2B ) nor IFN-g production ( fig. S7C ) was observed upon coculture of OR8B3 T190I-and MRPS5 P59L-specific T cells with DM6 cells expressing AAS-TMCs; this finding suggests that these neoantigens are not processed and presented from endogenously expressed protein. None of the neoantigen-specific T cells recognized wild typeencoding TMCs (Fig. 2B and fig. S7C ).
On the basis of these findings and the immune monitoring results (Fig. 1B) , the nine neoantigens identified in this study fall into three distinct antigenic determinant categories (18, 19) . TMEM48 F169L, SEC24A P469L, and EXOC8 Q656P represent dominant antigens, as T cell immunity was detected prior to vaccination (naturally occurring) (Fig. 1B) and these neoantigens were processed and presented from endogenously expressed protein (Fig. 2B) . TKT R438W, CDKN2A E153K, AKAP13 Q285K, and PABPC1 R520Q are characterized as subdominant antigens, as T cell immunity required peptide vaccination (Fig. 1B) these neoantigens were processed and presented from endogenously expressed protein (Fig. 2B) . Finally, OR8B3 T190I and MRPS5 P59L constitute cryptic antigens, because peptide vaccination elicited T cell immunity even though these neoantigens were not processed from endogenously expressed protein.
To validate neoantigen processing and presentation, we performed proteomic analysis on peptides eluted from soluble HLA-A*02:01 molecules isolated from melanoma cells expressing a TMC encoding AAS candidates from a tumor of patient MEL218 (18, 19) . Reverse-phase highperformance liquid chromatography (RP-HPLC) was used to reduce the complexity and determine the elution profile of the pool of soluble HLA-A*02:01-restricted peptides presented by melanoma cells, as well as the synthetic AAS peptide mixture (Fig. 3, A and E) . The fractions corresponding to each synthetic peptide were subjected to nanoscale liquid chromatography-mass spectrometry (nano LC/MS). Extracted ion chromatograms revealed the presence of an eluted peptide with a retention time within 2 min of synthetic EXOC8 Q656P peptide in fraction 50 (Fig. 3B) . MS/MS fragmentation pattern comparison of the eluted and synthetic peptides ensured EXOC8 Q656P sequence identity and confirmed HLA-A*02:01 presentation of this dominant neoantigen (Fig.  3, C and D) . A similar analysis of fraction 44 demonstrated the HLA-A*02:01 presentation of subdominant neoantigen PABPC1 R520Q (Fig. 3,  E to H) . Together, these results show that two of the seven neoantigens included in patient MEL218 vaccine, along with antigen controls WNV SVG9 and G280 ( fig. S8) , are processed and presented in the context of HLA-A*02:01 molecules.
Little is known about the composition and diversity of neoantigen-specific T cells (20, 21) or about the effect vaccination may have on these repertoires. To address this question, we generated reference T cell receptor-b (TCR-b) complementaritydetermining region 3 (CDR3) sequence libraries ( fig. S9 and tables S6 to S10) from short-term expanded sorted neoantigen-specific T cells (97 to 99% dextramer-positive; fig. S10 ) and used them to characterize neoantigen TCR-b clonotypes in purified CD8 + T cells isolated from pre-and postvaccine PBMC samples (22) (23) (24) . In prevaccination CD8 + T cell populations, as few as 1 and as many as 10 unique TCR-b clonotypes per neoantigen were identified (Fig. 4A) . Vaccination increased the frequency of most existing prevaccine TCR-b clonotypes and revealed previously undetected clonotypes for all six neoantigens (Fig. 4A) . For both dominant and subdominant neoantigens, the TCR-b repertoire was increased significantly after vaccination (Fig. 4) . For example, 84 clonotypes representing 19 TCR-b families were detected for TKT R438W, 61 clonotypes representing 12 TCR-b families were detected for SEC24A P469L, and 12 clonotypes representing 8 TCR-b families were detected for EXOC8 Q656P (Fig. 4B) . Thus, peptide vaccination with functionally mature dendritic cells may promote the expansion of a highly diverse neoantigen TCR repertoire.
Our results indicate that vaccination with highaffinity, patient-specific, tumor-derived mutant peptides augments T cell immunity directed at naturally occurring (dominant) neoantigens and expands the breadth of the antitumor immune response by revealing subdominant neoantigens (25) . Vaccination against tumor neoantigens appears safe, as all three patients are alive and well with no autoimmune adverse events. Inclusion of subdominant neoantigens into any therapeutic strategy would be expected to exert pressure to reduce the selection of antigen loss variants, especially in the setting of clonal tumor evolution (26) , which occurs with targeted agents such as BRAF inhibition in melanoma (27, 28) . The revelation of a highly diverse TCR-b repertoire specific for dominant and subdominant neoantigens was surprising and points to a potentially rich pool of naïve tumor-specific T cells that remain ignorant unless activated by vaccination. The effect of prior ipilimumab exposure on the prevaccine T cell repertoire in the three patients reported is unknown. However, recent data (29) indicate that administration of a CTLA-4 monoclonal antibody can influence TCR repertoire diversity in patients; this finding suggests a therapeutic strategy of testing checkpoint inhibitors, including ipilimumab, together with neoantigen vaccine formulations in order to further improve clinical outcomes. The paradigm described above could be applied to other malignancies presenting high mutational burdens, such as lung, bladder, and colorectal cancers (1) . Other categories of genomic alterations such as deletions, insertions, and frameshift mutations may also generate potential neoantigens; mining these neoantigens may be particularly relevant in malignancies with low mutational burden, such as leukemias (30) . Personalized immunotherapies targeting private somatic tumor alterations may become feasible in the near future. The centrosome organizes microtubule arrays within animal cells and comprises two centrioles surrounded by an amorphous protein mass called the pericentriolar material (PCM). Despite the importance of centrosomes as microtubule-organizing centers, the mechanism and regulation of PCM assembly are not well understood. In Caenorhabditis elegans, PCM assembly requires the coiled-coil protein SPD-5. We found that recombinant SPD-5 could polymerize to form micrometer-sized porous networks in vitro. Network assembly was accelerated by two conserved regulators that control PCM assembly in vivo, Polo-like kinase-1 and SPD-2/Cep192. Only the assembled SPD-5 networks, and not unassembled SPD-5 protein, functioned as a scaffold for other PCM proteins. Thus, PCM size and binding capacity emerge from the regulated polymerization of one coiled-coil protein to form a porous network.
P ericentriolar material (PCM), a matrix of proteins that regulates microtubule nucleation, anchoring, and dynamics (1, 2), assembles around centrioles to form centrosomes that contribute to cell division. The PCM scaffold is thought to form via the assembly of coiled-coil proteins [pericentrin and Cdk5RAP2/ centrosomin in vertebrates and Drosophila, and SPD-5 in Caenorhabditis elegans (3-8)]. PCM expansion during mitotic entry requires SPD-2/Cep192 and is regulated by mitotic kinases, including the Polo family kinase Plk1 (9-13). However, the mechanism of PCM assembly remains unclear, partly due to the lack of an in vitro system. In C. elegans, PCM assembly requires SPD-5, a protein with nine predicted coiled-coil domains (Fig. 1A) (7) . Because coiled-coil domains often mediate homo-oligomerization (14), we hypothesized that SPD-5 self-association could underlie PCM assembly. To test this idea, we purified fulllength, green fluorescent protein (GFP)-labeled SPD-5 (SPD-5::GFP) from baculovirus-infected insect cells (Fig. 1, A and B) (fig. S1A shows all proteins used in this study). Using total internal reflection microscopy to count GFP moieties in SPD-5::GFP particles by photobleaching revealed that SPD-5::GFP initially exists as monomers and dimers (Fig. 1C) , consistent with in vivo data (15) . To determine whether SPD-5 could form larger assemblies, we shifted SPD-5::GFP from ice to 23°C and observed samples using widefield fluorescence microscopy. After 120 min, 25 nM SPD-5:: GFP assembled into dense structures spanning several micrometers that we term "networks" (Fig. 1D) ; similar assemblies were observed by phase contrast microscopy using untagged SPD-5 ( fig. S1B ). Network formation decreased with lower initial SPD-5::GFP concentrations (Fig. 1D) . Temporal analysis using 25 nM SPD-5::GFP revealed single puncta that grew into extended meshworks (Fig. 1E) ; separate networks could also be observed coalescing during assembly ( fig. S1C ). SPD-5 networks readily dissolved after dilution or mechanical disruption, indicating that network formation is reversible ( fig. S1D) .
We calculated total SPD-5 network mass per sample by summing the integrated fluorescence intensity of all SPD-5::GFP networks (up to 200,000 per sample) in the imaged area (Fig. 1F) . We also calculated the size distribution of the networks in each sample ( fig. S1E ). The kinetics of SPD-5:: GFP network formation fit a sigmoidal curve typical of growing polymers, including a characteristic lag time and plateau (Fig. 1F) . Thus, SPD-5 alone can polymerize in vitro in a concentration and time-dependent manner to form extended networks that reach sizes comparable to fully expanded PCM in vivo (11) . Low-magnification cryo-electron microscopy of SPD-5 networks revealed dense, amorphous assemblies interspersed
